Humana Says Acthar's Meteoric Price Hike Cost It $700M

Law360 (August 9, 2019, 10:09 PM EDT) -- Mallinckrodt ran "one of the most outrageous price-gouging schemes in the history of American medicine" on its hormone gel used primarily to treat an infant seizure syndrome, according to a new suit filed by Humana, which says the scheme has cost it more than $700 million. 

The insurance giant laid out the accusations Thursday, telling a California federal court that pharmaceutical company Mallinckrodt ARD LLC used a three-pronged plan to keep its hormone gel Acthar at the top of the market despite the skyrocketing price.

A vial of Acthar, a drug that has been in circulation since the 1950s, has climbed to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS